CJC-1295 vs AICAR
Head-to-head comparison of CJC-1295 and AICAR for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Aicar |
|---|---|---|
| Category | Growth Hormone Secretagogue | Metabolic / Exercise Mimetic |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to ZMP (AICA ribotide), an AMP analog. |
| Evidence Rating | D — Preclinical | C — Early Human or Mixed Evidence |
| Clinical Status | Research-only / Not approved for human use | Phase II/III clinical trials for cardiac ischemia (acadesine). WADA-banned metabolic modulator. No FDA approval. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | In clinical trials (IV acadesine): transient hyperuricemia, mild hypoglycemia at higher doses; Injection site reactions with SC administration |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 1000-5000 mcg per injection |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~258.2 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~1.5-3 hours |
Overview
CJC-1295 and AICAR are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
AICAR — Mechanism & Evidence
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a cell-permeable nucleoside analog (MW ~258.2 g/mol) that is phosphorylated intracellularly to ZMP, which directly activates AMP-activated protein kinase (AMPK). As an exercise mimetic, it triggers many of the same metabolic adaptations as physical exercise — including enhanced glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and improved insulin sensitivity — without requiring muscular contraction. It has been studied in Phase II/III trials for cardiac ischemia and is banned by WADA as a metabolic modulator.
Key claims: Mimics exercise-induced metabolic adaptations; Enhances fatty acid oxidation; Improves insulin sensitivity.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
AICAR is also researched for: Metabolic Health.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
AICAR: In clinical trials (IV acadesine): transient hyperuricemia, mild hypoglycemia at higher doses Injection site reactions with SC administration Theoretical risk of lactic acidosis with excessive AMPK activation
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe